Modeling meningococcal A conjugate vaccine coverage in the meningitis belt from 2010 to 2019

Rose Bender[1,3], Jasmine Shen[2,3], Jon Mosser[1,3], Hmwe Kyu[1,3]

[1] Department of Health Metrics, University of Washington, USA; [2] School of Medicine, University of Washington, USA; [3] Institute for Health Metrics and Evaluation, University of Washington, USA

SUMMARY

This study synthesizes campaign coverage data with routine immunization data to produce estimates of MACV coverage in all meningitis belt countries, from 2010 to 2019, for the 1 to 4 and 1 to 29 age groups.

DATA

We compiled data sources for MenAfriVac routine immunization coverage from 2010 to 2019 via systematic review, and campaign coverage via published WHO report[1].

Mass campaigns	Catchup campaigns	Routine immunization
• Admin & survey data published by WHO	• Admin & survey data published by WHO	• Admin & survey from WHO JRF, systematic literature review

METHODS



RESULTS



IMPLICATIONS AND CONCLUSIONS

Overall, MenAfriVac mass campaigns have been highly successful; however, without routine immunization, the protection they provide diminishes over time. These estimates help to highlight gaps in MenA immunity, and emphasize the need for routine immunization in countries where past campaigns are the only source of immunity.

REFERENCES

1. Bwaka, A. et al. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018. *J Infect Dis* 220, S140–S147 (2019).

ACKNOWLEDGMENTS

Thank you to Prof. Laura Dwyer-Lindgren, and my capstone course classmates, for their ongoing feedback. Thank you also to IHME's Vaccine Preventable Diseases Team for help with data identification and modeling. Funding: none